A confirmatory study of APTA-2217 [roflumilast] in patients with chronic obstructive pulmonary disease (a placebo-controlled double-blind comparative study).

Trial Profile

A confirmatory study of APTA-2217 [roflumilast] in patients with chronic obstructive pulmonary disease (a placebo-controlled double-blind comparative study).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 04 May 2012 Additional companies (Mitsubishi Tanabe Pharma Corporation, Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov (Parent trial: NCT00242294).
    • 04 May 2012 Additional lead trial investigator (Cullmann G) added as reported by ClinicalTrials.gov.
    • 14 Dec 2008 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top